Accurate detection of BRAF p. V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular …
KE Fisher, C Cohen, MT Siddiqui, JF Palma… - Human pathology, 2014 - Elsevier
Malignant melanoma patients require BRAF mutation testing prior to initiating BRAF inhibitor
therapy. Molecular testing remains the diagnostic gold standard, but recent work suggests
that BRAF immunohistochemistry (IHC) confers comparable results. Sample attributes and
scoring criteria that may affect BRAF IHC interpretation, however, are poorly defined. We
investigated formalin-fixed, paraffin-embedded samples with variable challenging
interpretative attributes: metastases, core needle biopsies, sample tissues less than 60 mm …
therapy. Molecular testing remains the diagnostic gold standard, but recent work suggests
that BRAF immunohistochemistry (IHC) confers comparable results. Sample attributes and
scoring criteria that may affect BRAF IHC interpretation, however, are poorly defined. We
investigated formalin-fixed, paraffin-embedded samples with variable challenging
interpretative attributes: metastases, core needle biopsies, sample tissues less than 60 mm …
以上显示的是最相近的搜索结果。 查看全部搜索结果